FBRX
Forte Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.99
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +42.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -92.7%
- EBIT
- -93.0%
- Net income
- -95.5%
- EPS
- +61.3%
- Free cash flow
- -65.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026